News
Many Mounjaro users have considered making the swap after Eli Lilly announced prices would be increasing in the UK by 170 percent ...
The U.S. and European Union had first struck a trade agreement in July, but many details were left unresolved at the time.
Viking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The ...
European stocks fell Thursday as investors weighed ongoing concerns about the artificial-intelligence boom and data showing gains in business activity. The composite purchasing managers' index for the ...
Demand for Novo Nordisk A/S’s weight-loss blockbuster Wegovy is getting a boost in the UK from an unexpected corner: ...
In people with recently diagnosed type 2 diabetes and no prior cardiovascular disease, self-reported physical activity ...
GMO’s 13F portfolio grew to $33.23B in Q2 2025, with Microsoft, Meta, Alphabet, Oracle, and Apple as top holdings. Read more ...
Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.
A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.
Sure, nobody goes around boasting, "We're Number Two!" But in certain circumstances, coming in second has its advantages.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results